And while it's investigating those reports of blood clots, Hewitt says that it thinks that the virtues of the Oxford AstraZeneca virus far outweigh any risks because the EU needs vaccines, it doesn't have enough of them anyway here because there's been problems with delivery, and even with the vaccines that the EU has, many countries have had lots of stumbling blocks with their national roll roll outs.
而它在調查那些血栓的報告的同時,休伊特表示,它認為牛津阿斯利康病毒的優點遠遠大於任何風險,因為歐盟需要疫苗,反正它這裡的疫苗也不夠多,因為在交付方面一直存在問題,即使歐盟有的疫苗,很多國家在全國推廣時也遇到了很多絆腳石。